Literature DB >> 10071676

Striking cholestatic liver disease: a distinct manifestation of advanced primary amyloidosis.

D C Rockey1.   

Abstract

In patients with systemic amyloidosis, amyloid fibrils are typically deposited in numerous organs, including the kidneys, heart, and liver. Although amyloid deposition in the liver is common in patients with systemic amyloidosis, clinical liver disease is relatively rare. The patient described here had cholestatic liver disease as the primary manifestation of primary systemic amyloidosis. Review of the literature suggests that prominent liver disease with cholestasis is unusual but probably underreported in patients with amyloidosis and appears to be restricted to patients with the primary form of amyloidosis. Nonetheless, cholestatic hepatic amyloidosis is characterized by distinct clinical, laboratory, and pathologic features; recognition of this process is critical because it identifies patients with widespread organ involvement and portends a poor prognosis.

Entities:  

Mesh:

Year:  1999        PMID: 10071676     DOI: 10.1097/00007611-199902000-00016

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  6 in total

1.  Subacute liver failure secondary to amyloid light-chain amyloidosis.

Authors:  Theresa J Hydes; Richard J Aspinall
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-03

2.  A man with new onset of ascites and edema.

Authors:  Melvin Lau
Journal:  Medscape J Med       Date:  2008-04-09

3.  Acute liver failure due to primary amyloidosis in a nephrotic syndrome: a swiftly progressive course.

Authors:  Brigite Aguiar Cardoso; Rita Leal; Helena Sá; Mário Campos
Journal:  BMJ Case Rep       Date:  2016-03-10

4.  Primary Amyloidosis Manifesting as Cholestatic Jaundice after Laparoscopic Cholecystectomy.

Authors:  Evangelos P Misiakos; George Bagias; Dina Tiniakos; Konstantinos Roditis; Nick Zavras; Ioannis Papanikolaou; Panagiotis Tsirigotis; Theodore Liakakos; Anastasios Machairas
Journal:  Case Rep Surg       Date:  2015-06-07

5.  Myeloma-associated systemic amyloidosis masquerading as NASH-associated cirrhosis and diabetic microvascular complications.

Authors:  Partha Pal; Sayantan Ray; Sisir Kumar Patra; Anjan Kumar Das; Subhasis Dey; Rintu George
Journal:  Oxf Med Case Reports       Date:  2015-04-13

6.  Response of Bortezomib Chemotherapy in Hepatic Amyloidosis.

Authors:  Syed M Hasan; Nida N Ahmed; Zunirah Ahmed; Allan Seibert
Journal:  J Investig Med High Impact Case Rep       Date:  2018-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.